If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
This partnership stemmed from a successful customer-supplier relationship spanning several years.
Tislelizumab is now approved in nine indications in China
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Deputy Mayor from Addis Ababa (Ethiopia) battled out a rare laryngeal cancer at Yashoda Hospitals Hyderabad
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
Second interchangeable biosimilar product approved by agency
The medicine is now approved for eight indications across five different types of cancer in China.
The company is eligible for 12 months exclusivity from launch
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)